

Express Mail Label No. EV 409530457 US  
Attorney Docket No. 6296.204-US  
Serial No. 09/853,193; Filed: May 11, 2001

### **Amendments To The Claims**

The listing of claims will replace all prior versions, and listings, of the claims in the application.

### **Listing Of Claims:**

Claim 1 (Currently Amended) A method of treating a critically ill patient or a critically ill polyneuropathy (CIPNP)-patient, said method comprising administering ~~a blood-glucose regulator~~ insulin, an insulin analogue, an active derivative of insulin or an insulin analogue, or a physiologically acceptable salt of said derivative to said critically ill patient or said CIPNP-patient in an amount effective to maintain blood glucose levels in said patient within a range of from about 60 mg/dL to about 130 mg/dL.

Claims 2-3 (Cancelled)

Claim 4 (Currently Amended) A method of treating a patient suffering from CIPNP, said method comprising treating said patient with ~~a blood-glucose regulator~~ insulin, an insulin analogue, an active derivative of insulin or an insulin analogue, or a physiologically acceptable salt of said derivative in an amount effective to treat said CIPNP.

Claims 5-6 (Cancelled)

Claim 7 (Currently Amended)) The method of claim 4, wherein the ~~blood-glucose-regulator~~ insulin, insulin analogue, active derivative of insulin or the insulin analogue, or a physiologically acceptable salt of said derivative is administered in an amount effective to maintain blood glucose levels in said patient within a range of from about 60 mg/dL to about 130 mg/dL.

Claim 8 (Previously presented) The method of claim 7, wherein said blood glucose levels are maintained within a range of from about 80 mg/dL to about 110 mg/dL.

Express Mail Label No. EV 409530457 US  
Attorney Docket No. 6296.204-US  
Serial No. 09/853,193; Filed: May 11, 2001

Claim 9 (Previously presented) The method of claim 4, wherein said blood glucose levels are maintained for 8 hours or more.

Claim 10 (Previously presented) The method of claim 9, wherein said blood glucose levels are maintained for 24 hours or more.

Claim 11 (Previously presented) The method of claim 10, wherein said blood glucose levels are maintained for 4 days or more.

Claim 12 (Previously presented) The method of claim 4, wherein the patient is a mammal.

Claim 13 (Previously Presented) The method of claim 12, wherein the patient is a human.

Claim 14 (Previously Presented) The method of claim 13, wherein the patient is non-diabetic.

Claims 15-21 (Cancelled)

Claim 22 (Currently Amended) The method of claim 1, wherein said ~~blood glucose regulator insulin, an insulin analogue, an active derivative of insulin or the insulin analogue, or a physiologically acceptable salt of said derivative~~ is administered to said critically ill patient or to said CIPNP patient in an amount effective to maintain blood glucose levels in said patient within a range from about 70 mg/dL to about 120 mg/dL.

Claim 23 (Currently Amended) The method of claim 1, wherein said ~~blood glucose regulator insulin, insulin analogue, active derivative of insulin or the insulin analogue, or a physiologically acceptable salt of said derivative~~ is administered to said critically ill patient or to said CIPNP patient in an amount effective to maintain blood glucose levels in said patient within a range from about 80 mg/dL to about 110 mg/dL.

Claim 24 (Previously presented) The method of claim 1, wherein said blood glucose levels are maintained within a range from about 60 mg/dL to about 130 mg/dL for 8 hours or more.

Claim 25 (Previously presented) The method of claim 1, wherein said blood glucose levels are

Express Mail Label No. EV 409530457 US  
Attorney Docket No. 6296.204-US  
Serial No. 09/853,193; Filed: May 11, 2001

maintained within a range from about 60 mg/dL to about 130 mg/dL for 24 hours or more.

Claim 26 (Previously presented) The method of claim 1, wherein said blood glucose levels are maintained within a range from about 60 mg/dL to about 130 mg/dL for 4 days or more.

Claim 27 (Previously presented) The method of claim 1, wherein the patient is a mammal.

Claim 28 (Previously presented) The method of claim 27, wherein the patient is a human.

Claim 29 (Previously presented) The method of claim 28, wherein the patient is non-diabetic.

Claims 30-31 (Cancelled)

Claim 32 (New) The method of claim 1, wherein an insulin analogue is administered to said critically ill patient or CIPNP patient.

Claim 33 (New) The method of claim 32, wherein said insulin analogue is Asp<sup>B28</sup> human insulin.

Claim 34 (New) The method of claim 32, wherein said insulin analogue is Lys<sup>B28</sup>, Pro<sup>B29</sup> human insulin.

Claim 35 (New) The method of claim 1, wherein an active derivative of an insulin analogue or a physiologically acceptable salt of said derivative is administered to said critically ill patient or CIPNP patient.

Claim 36 (New) The method of claim 35, wherein said active derivative of an insulin analogue is des-Thr<sup>B30</sup> human insulin γ Lys<sup>B29</sup> tetradecanoyl.

Claim 37 (New) The method of claim 1, wherein Insulin is administered to said critically ill patient or CIPNP patient.

Claim 38 (New) The method of claim 37, wherein said insulin is human insulin.

Express Mail Label No. EV 409530457 US  
Attorney Docket No. 6296.204-US  
Serial No. 09/853,193; Filed: May 11, 2001

Claim 39 (New) The method of claim 1, wherein said insulin, insulin analogue, active derivative of insulin or an insulin analogue, or physiologically acceptable salt of said derivative is administered intravenously.

Claim 40 (New) The method of claim 32, wherein said insulin analogue is administered intravenously.

Claim 41 (New) The method of claim 33, wherein said Asp<sup>B28</sup> human insulin is administered intravenously.

Claim 42 (New) The method of claim 34, wherein said Lys<sup>B28</sup>, Pro<sup>B29</sup> human insulin is administered intravenously.

Claim 43 (New) The method of claim 35, wherein said active derivative of an insulin analogue or a physiologically acceptable salt of said derivative is administered intravenously.

Claim 44 (New) The method of claim 36, wherein said des-Thr<sup>B30</sup> human insulin γ Lys<sup>B29</sup> tetradecanoyl is administered intravenously.

Claim 45 (New) The method of claim 37, wherein said insulin is administered intravenously.

Claim 46 (New) The method of claim 38, wherein said human insulin is administered intravenously.

Claim 47 (New) The method of claim 4, wherein an insulin analogue is administered to said CIPNP patient.

Claim 48 (New) The method of claim 47, wherein said insulin analogue is Asp<sup>B28</sup> human Insulin.

Claim 49 (New) The method of claim 47, wherein said insulin analogue is Lys<sup>B28</sup>, Pro<sup>B29</sup> human insulin.

Claim 50 (New) The method of claim 4, wherein an active derivative of an Insulin analogue or a

Express Mail Label No. EV 409530457 US  
Attorney Docket No. 6296.204-US  
Serial No. 09/853,193; Filed: May 11, 2001

physiologically acceptable salt of said derivative is administered to said CIPNP patient.

Claim 51 (New) The method of claim 50, wherein said active derivative of an insulin analogue is des-Thr<sup>B30</sup> human insulin  $\gamma$  Lys<sup>B29</sup> tetradecanoyl.

Claim 52 (New) The method of claim 4, wherein insulin is administered to said CIPNP patient.

Claim 53 (New) The method of claim 52, wherein said insulin is human insulin.

Claim 54 (New) The method of claim 4, wherein said insulin, insulin analogue, active derivative of insulin or an insulin analogue, or physiologically acceptable salt of said derivative is administered intravenously.

Claim 55 (New) The method of claim 47, wherein said insulin analogue is administered intravenously.

Claim 56 (New) The method of claim 48, wherein said Asp<sup>B28</sup> human insulin is administered intravenously.

Claim 57 (New) The method of claim 49, wherein said Lys<sup>B26</sup>, Pro<sup>B29</sup> human insulin is administered intravenously.

Claim 58 (New) The method of claim 50, wherein said active derivative of an insulin analogue or a physiologically acceptable salt of said derivative is administered intravenously.

Claim 59 (New) The method of claim 51, wherein said des-Thr<sup>B30</sup> human insulin  $\gamma$  Lys<sup>B29</sup> tetradecanoyl is administered intravenously.

Claim 60 (New) The method of claim 52, wherein said insulin is administered intravenously.

Claim 61 (New) The method of claim 53, wherein said human insulin is administered intravenously.